Home ETF List About

Portfolio Holdings Detail for ISIN IE00BYXG2H39
Stock Name / FundiShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
IssuerBlackrock
Entity holding fund iShares IV Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF TickerBTEC(USD) LSE
ETF TickerBTEK(GBP) LSE
ETF Ticker2B70(EUR) F
ETF Ticker2B70.DE(EUR) CXE
ETF TickerBTEC.LS(USD) CXE
ETF TickerBTEK.LS(GBP) CXE
ETF TickerBTEC.L(GBP) LSE
ETF TickerBTEK.L(GBP) LSE

Holdings detail for RCKT

Stock NameRocket Pharmaceuticals Inc
TickerRCKT(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS77313F1066
LEI549300R7VV82YUIN4Y93

Show aggregate RCKT holdings

News associated with RCKT

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives $16.73 Consensus Price Target from Brokerages
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) has been given an average recommendation of “Hold” by the seventeen research firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, eight have issued a hold recommendation and eight have issued a buy recommendation on […] - 2025-09-08 03:08:52
Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Rating Upgraded by Bank of America
Bank of America upgraded shares of Rocket Pharmaceuticals (NASDAQ:RCKT – Free Report) from a neutral rating to a buy rating in a research note issued to investors on Wednesday, Marketbeat.com reports. They currently have $10.00 price objective on the biotechnology company’s stock, up from their prior price objective of $4.00. Several other equities analysts also […] - 2025-08-21 04:58:50
Pre-Market Most Active for Aug 20, 2025 : OPEN, RCKT, TSLL, SQQQ, PLTR, NVDA, TGT, NIO, BBAI, ZIM, JHX, ACHR
The NASDAQ 100 Pre-Market Indicator is down -41.62 to 23,343.15. The total Pre-Market volume is currently 119,921,297 shares traded.The following are the most active stocks for the pre-market session: Opendoor Technologies Inc (OPEN) is -0.18 at $3.44, with 13,354,852 shares tra - 2025-08-20 09:29:56
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Average Rating of “Hold” from Brokerages
Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) have been given an average recommendation of “Hold” by the seventeen analysts that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and seven have given a buy rating […] - 2025-08-11 02:48:58
Canaccord Genuity Group Cuts Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target to $10.00
Rocket Pharmaceuticals (NASDAQ:RCKT – Free Report) had its target price trimmed by Canaccord Genuity Group from $11.00 to $10.00 in a research report released on Friday morning,Benzinga reports. The firm currently has a buy rating on the biotechnology company’s stock. Other research analysts also recently issued reports about the stock. UBS Group reduced their target […] - 2025-07-28 04:40:54
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives $18.60 Consensus Target Price from Analysts
Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) have been given a consensus recommendation of “Hold” by the seventeen analysts that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and eight have given a buy rating to the […] - 2025-06-25 03:02:58
Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Rating Lowered by The Goldman Sachs Group
Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report) was downgraded by analysts at The Goldman Sachs Group from a “neutral” rating to a “sell” rating in a research report issued to clients and investors on Wednesday, Marketbeat reports. A number of other research firms have also recently weighed in on RCKT. JPMorgan Chase & Co. cut […] - 2025-05-30 04:34:55
Chardan Capital Lowers Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target to $17.00
Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report) had its price target reduced by research analysts at Chardan Capital from $46.00 to $17.00 in a report released on Wednesday, MarketBeat.com reports. The firm presently has a “buy” rating on the biotechnology company’s stock. RCKT has been the topic of several other research reports. Jefferies Financial Group […] - 2025-05-30 04:34:54
Morgan Stanley Reiterates Equal Weight Rating for Rocket Pharmaceuticals (NASDAQ:RCKT)
Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report)‘s stock had its “equal weight” rating restated by equities researchers at Morgan Stanley in a note issued to investors on Wednesday, MarketBeat Ratings reports. They currently have a $7.00 target price on the biotechnology company’s stock. Morgan Stanley’s target price suggests a potential upside of 167.18% from the […] - 2025-05-30 04:34:51
Jefferies Financial Group Reiterates “Hold” Rating for Rocket Pharmaceuticals (NASDAQ:RCKT)
Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report)‘s stock had its “hold” rating reiterated by equities research analysts at Jefferies Financial Group in a research report issued to clients and investors on Wednesday, Marketbeat.com reports. Other equities research analysts have also recently issued research reports about the company. JPMorgan Chase & Co. cut their target price […] - 2025-05-30 02:16:46
Rocket Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:RCKT)
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) saw unusually large options trading on Tuesday. Traders acquired 2,414 call options on the company. This is an increase of 426% compared to the typical volume of 459 call options. Rocket Pharmaceuticals Stock Performance RCKT opened at $2.48 on Thursday. The stock’s 50 day simple moving average […] - 2025-05-29 05:14:57
BMO Capital Markets Issues Pessimistic Forecast for Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price
Rocket Pharmaceuticals (NASDAQ:RCKT – Free Report) had its price target trimmed by BMO Capital Markets from $30.00 to $8.00 in a research report sent to investors on Wednesday,Benzinga reports. The brokerage currently has an outperform rating on the biotechnology company’s stock. Several other equities analysts also recently commented on the stock. Cantor Fitzgerald upped their […] - 2025-05-29 04:40:53
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Buys 3,985 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Free Report) by 2.3% in the 4th quarter, HoldingsChannel reports. The fund owned 177,548 shares of the biotechnology company’s stock after buying an additional 3,985 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.’s holdings in Rocket Pharmaceuticals were […] - 2025-05-22 05:51:02
Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target Raised to $30.00
Rocket Pharmaceuticals (NASDAQ:RCKT – Free Report) had its price target increased by Cantor Fitzgerald from $20.00 to $30.00 in a research report sent to investors on Friday morning,Benzinga reports. They currently have an overweight rating on the biotechnology company’s stock. Cantor Fitzgerald also issued estimates for Rocket Pharmaceuticals’ FY2025 earnings at ($2.28) EPS. RCKT has […] - 2025-05-19 03:12:47
Voya Investment Management LLC Sells 1,493 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)
Voya Investment Management LLC trimmed its stake in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Free Report) by 7.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 19,975 shares of the biotechnology company’s stock after selling 1,493 shares […] - 2025-05-13 05:20:49
Canaccord Genuity Group Has Lowered Expectations for Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price
Rocket Pharmaceuticals (NASDAQ:RCKT – Free Report) had its target price cut by Canaccord Genuity Group from $36.00 to $34.00 in a research report report published on Monday,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock. A number of other equities analysts have also issued reports on the stock. Scotiabank raised their […] - 2025-05-13 02:56:45
Raymond James Financial Inc. Makes New $285,000 Investment in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)
Raymond James Financial Inc. acquired a new position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Free Report) during the 4th quarter, HoldingsChannel.com reports. The firm acquired 22,645 shares of the biotechnology company’s stock, valued at approximately $285,000. Several other large investors have also recently bought and sold shares of the company. SG Americas Securities […] - 2025-05-12 04:20:58
Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target Lowered to $45.00 at Chardan Capital
Rocket Pharmaceuticals (NASDAQ:RCKT – Free Report) had its price objective decreased by Chardan Capital from $54.00 to $45.00 in a research note issued to investors on Friday,Benzinga reports. Chardan Capital currently has a buy rating on the biotechnology company’s stock. Several other equities analysts also recently commented on the company. BMO Capital Markets assumed coverage […] - 2025-05-12 02:38:47
Mariner LLC Takes Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)
Mariner LLC bought a new position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 11,061 shares of the biotechnology company’s stock, valued at approximately $139,000. Other institutional investors […] - 2025-05-09 04:36:56
Analysts Set Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) PT at $43.00
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) has earned a consensus rating of “Moderate Buy” from the twelve research firms that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and eleven have issued a buy recommendation on the company. The average 1 […] - 2025-05-06 03:07:08
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Bought by Legal & General Group Plc
Legal & General Group Plc raised its holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Free Report) by 3.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 75,454 shares of the biotechnology company’s stock after purchasing an additional 2,416 shares during the quarter. […] - 2025-04-28 04:56:54
Raymond James Financial Inc. Acquires Shares of 22,645 Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)
Raymond James Financial Inc. acquired a new position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Free Report) during the 4th quarter, HoldingsChannel.com reports. The institutional investor acquired 22,645 shares of the biotechnology company’s stock, valued at approximately $285,000. Other hedge funds and other institutional investors have also made changes to their positions in the […] - 2025-04-11 04:56:49
Mitsubishi UFJ Asset Management Co. Ltd. Has $254,000 Holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)
Mitsubishi UFJ Asset Management Co. Ltd. increased its position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Free Report) by 68.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 20,196 shares of the biotechnology company’s stock after buying an additional 8,190 […] - 2025-04-04 05:12:55
Blair William & Co. IL Reduces Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)
Blair William & Co. IL reduced its stake in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Free Report) by 14.0% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 116,038 shares of the biotechnology company’s stock after selling 18,931 shares during the quarter. Blair William & Co. IL’s holdings in Rocket Pharmaceuticals were worth […] - 2025-04-03 05:27:07
Teacher Retirement System of Texas Purchases 7,211 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)
Teacher Retirement System of Texas raised its position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Free Report) by 45.2% during the 4th quarter, Holdings Channel reports. The fund owned 23,148 shares of the biotechnology company’s stock after purchasing an additional 7,211 shares during the period. Teacher Retirement System of Texas’ holdings in Rocket Pharmaceuticals […] - 2025-04-02 04:42:48
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Bought by Signaturefd LLC
Signaturefd LLC grew its holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Free Report) by 319.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,916 shares of the biotechnology company’s stock after buying an additional 3,745 shares during the quarter. Signaturefd LLC’s holdings […] - 2025-03-25 06:03:00
Harbour Investments Inc. Acquires 1,840 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)
Harbour Investments Inc. lifted its holdings in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Free Report) by 51.9% in the fourth quarter, HoldingsChannel.com reports. The fund owned 5,385 shares of the biotechnology company’s stock after acquiring an additional 1,840 shares during the period. Harbour Investments Inc.’s holdings in Rocket Pharmaceuticals were worth $68,000 as of […] - 2025-03-24 06:02:55
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) have been given an average rating of “Moderate Buy” by the twelve analysts that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company. The […] - 2025-03-14 05:12:56
Canaccord Genuity Group Has Lowered Expectations for Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price
Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report) had its price target lowered by research analysts at Canaccord Genuity Group from $39.00 to $36.00 in a research note issued on Monday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Canaccord Genuity Group’s price objective would indicate a potential upside of 315.70% […] - 2025-03-05 08:08:58
Rocket Pharmaceuticals (NASDAQ:RCKT) Sets New 1-Year Low on Analyst Downgrade
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) shares reached a new 52-week low on Monday after The Goldman Sachs Group lowered their price target on the stock from $29.00 to $15.00. The Goldman Sachs Group currently has a neutral rating on the stock. Rocket Pharmaceuticals traded as low as $8.93 and last traded at […] - 2025-03-04 04:56:43

iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) RCKT holdings

DateNumber of RCKT Shares HeldBase Market Value of RCKT SharesLocal Market Value of RCKT SharesChange in RCKT Shares HeldChange in RCKT Base ValueCurrent Price per RCKT Share HeldPrevious Price per RCKT Share Held
2025-11-11 (Tuesday)68,648USD 223,792USD 223,792
2025-11-10 (Monday)68,648RCKT holding increased by 181USD 216,241RCKT holding decreased by -799USD 216,241181USD -799 USD 3.15 USD 3.16999
2025-11-07 (Friday)68,467USD 217,040RCKT holding decreased by -4108USD 217,0400USD -4,108 USD 3.16999 USD 3.22999
2025-11-06 (Thursday)68,467RCKT holding increased by 180USD 221,148RCKT holding decreased by -5565USD 221,148180USD -5,565 USD 3.22999 USD 3.32
2025-11-05 (Wednesday)68,287USD 226,713RCKT holding increased by 2049USD 226,7130USD 2,049 USD 3.32 USD 3.29
2025-11-04 (Tuesday)68,287RCKT holding increased by 181USD 224,664RCKT holding decreased by -17793USD 224,664181USD -17,793 USD 3.29 USD 3.55999
2025-11-03 (Monday)68,106USD 242,457RCKT holding decreased by -14303USD 242,4570USD -14,303 USD 3.55999 USD 3.77001
2025-10-31 (Friday)68,106USD 256,760RCKT holding increased by 4768USD 256,7600USD 4,768 USD 3.77001 USD 3.7
2025-10-30 (Thursday)68,106RCKT holding increased by 905USD 251,992RCKT holding decreased by -2028USD 251,992905USD -2,028 USD 3.7 USD 3.78
2025-10-29 (Wednesday)67,201RCKT holding increased by 362USD 254,020RCKT holding decreased by -11331USD 254,020362USD -11,331 USD 3.78 USD 3.97
2025-10-28 (Tuesday)66,839USD 265,351RCKT holding increased by 2005USD 265,3510USD 2,005 USD 3.97 USD 3.94001
2025-10-27 (Monday)66,839USD 263,346RCKT holding increased by 6016USD 263,3460USD 6,016 USD 3.94001 USD 3.85
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of RCKT by Blackrock for IE00BYXG2H39

Show aggregate share trades of RCKT

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-11-10BUY1813.2303.120 3.131USD 567 7.52
2025-11-06BUY1803.3503.160 3.179USD 572 7.56
2025-11-04BUY1813.5303.285 3.310USD 599 7.61
2025-10-30BUY9053.8403.690 3.705USD 3,353 7.67
2025-10-29BUY3623.7803.945 3.928USD 1,422 7.69
2025-10-22SELL-7163.8003.970 3.953USD -2,830 7.79 Profit of 2,748 on sale
2025-10-20BUY3584.0004.065 4.059USD 1,453 7.83
2025-10-17BUY8933.7103.939 3.916USD 3,497 7.86
2025-10-15BUY1,4164.2404.509 4.482USD 6,347 7.88
2025-10-03BUY1,2813.1503.270 3.258USD 4,173 7.92
2025-10-02BUY1833.2103.280 3.273USD 599 7.95
2025-09-30BUY3643.2603.290 3.287USD 1,196 8.00
2025-09-26BUY3643.2603.260 3.260USD 1,187 8.06
2025-09-25BUY3643.1903.280 3.271USD 1,191 8.09
2025-09-18BUY1833.1703.170 3.170USD 580 8.14
2025-09-17BUY5493.0303.255 3.233USD 1,775 8.17
2025-08-21SELL-7283.7303.875 3.861USD -2,810 8.26 Profit of 3,201 on sale
2025-07-30BUY7163.1403.360 3.338USD 2,390 8.48
2025-07-17SELL-3603.3403.520 3.502USD -1,261 8.80 Profit of 1,906 on sale
2025-07-11SELL-1,4562.9603.140 3.122USD -4,546 8.96 Profit of 8,496 on sale
2025-07-07BUY5462.8102.920 2.909USD 1,588 9.12
2025-07-02BUY10,0102.8802.940 2.934USD 29,369 9.21
2025-06-11BUY3643.0303.330 3.300USD 1,201 9.59
2025-06-10BUY3643.1603.230 3.223USD 1,173 9.64
2025-06-04SELL-1822.9203.120 3.100USD -564 9.85 Profit of 1,229 on sale
2025-04-23BUY1777.1407.440 7.410USD 1,312 11.01
2025-04-10SELL-1,4244.9405.400 5.354USD -7,624 11.49 Profit of 8,745 on sale
2025-04-08SELL-1784.7905.480 5.411USD -963 11.64 Profit of 1,109 on sale
2025-04-07SELL-1785.1905.300 5.289USD -941 11.72 Profit of 1,144 on sale
2025-04-04SELL-8905.1205.435 5.403USD -4,809 11.79 Profit of 5,688 on sale
2025-04-01BUY7285.8106.650 6.566USD 4,780 11.93
2025-03-31SELL-5346.6707.275 7.215USD -3,853 12.00 Profit of 2,554 on sale
2025-03-21BUY9,5778.4308.700 8.673USD 83,061 12.31
2025-03-14SELL-2,3528.7608.810 8.805USD -20,709 12.57 Profit of 8,858 on sale
2025-03-07SELL-2928.7709.110 9.076USD -2,650 12.87 Profit of 1,109 on sale
2025-03-04SELL-1478.6608.825 8.808USD -1,295 13.06 Profit of 625 on sale
2025-02-25BUY2929.36010.170 10.089USD 2,946 13.38
2025-02-19SELL-14510.92011.080 11.064USD -1,604 13.59 Profit of 367 on sale
2025-02-13BUY43510.12010.150 10.147USD 4,414 13.84
2025-02-12BUY1459.8609.870 9.869USD 1,431 13.92
2025-02-11BUY5809.88010.150 10.123USD 5,871 14.01
2024-12-30SELL-4,82912.03012.270 12.246USD -59,136 15.42 Profit of 15,310 on sale
2024-11-18SELL-2,35513.66014.250 14.191USD -33,420 17.18 Profit of 7,046 on sale
2024-11-08SELL-15717.45017.660 17.639USD -2,769 17.25 Loss of -62 on sale
2024-10-21SELL-15717.62018.870 18.745USD -2,943 0.00 Loss of -2,943 on sale
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of RCKT

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19563,0642,7151,108,58050.8%
2025-09-18353,57110944,62437.4%
2025-09-17645,8822,2961,194,28754.1%
2025-09-16195,6240653,20929.9%
2025-09-15462,7621,0281,038,97844.5%
2025-09-12444,8500857,65451.9%
2025-09-11334,9603,831760,21644.1%
2025-09-10232,3610582,56939.9%
2025-09-09386,6750927,05941.7%
2025-09-08192,0470513,69237.4%
2025-09-05164,3170692,42623.7%
2025-09-04350,3170986,37335.5%
2025-09-03468,3316501,309,07235.8%
2025-09-02234,9880793,31029.6%
2025-08-29610,0732,0001,209,94750.4%
2025-08-28629,77902,341,10726.9%
2025-08-27395,8863,0301,379,01428.7%
2025-08-26371,10401,528,87324.3%
2025-08-25480,95301,422,02533.8%
2025-08-221,263,1872,5663,984,21331.7%
2025-08-212,224,15827,8834,641,01647.9%
2025-08-2018,811,47768,38529,439,62863.9%
2025-08-19621,5671521,001,12262.1%
2025-08-18338,544101679,55249.8%
2025-08-15269,076166608,74444.2%
2025-08-14326,439180581,15256.2%
2025-08-13527,42401,350,76439.0%
2025-08-12439,9830946,92146.5%
2025-08-11544,6333,0001,045,69852.1%
2025-08-08824,5831501,428,67357.7%
2025-08-07401,6580805,25049.9%
2025-08-06406,5341,143942,46943.1%
2025-08-05417,2600901,99746.3%
2025-08-04275,1876,300534,22051.5%
2025-08-01329,543200720,27745.8%
2025-07-31300,5510628,54947.8%
2025-07-30768,47101,834,72241.9%
2025-07-29352,714923765,85646.1%
2025-07-28340,51301,133,96330.0%
2025-07-25359,76601,066,13133.7%
2025-07-24462,48221,0001,595,33729.0%
2025-07-23441,20301,579,84027.9%
2025-07-22425,7154501,791,95123.8%
2025-07-21476,2639,8771,518,34131.4%
2025-07-18546,8234241,687,39132.4%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.